You are viewing the site in preview mode

Skip to main content

Table 3 The comparison of scale scores based on psychiatric diagnoses for patients and the control group

From: Evaluation of the effect of the COVID-19 pandemic on depression, anxiety and psychological resilience in patients with primary immunodeficiency

  

Psychiatric Diagnosis

 

None (I)

Depressive disorder (II)

Anxiety disorders (III)

p value

Pairwise comparison

HAM-D

Patient group

4(0–20)

10(0–21)

5(0–17)

0.009

I-II: 0.007

I-III: 1.000

II-III: 0.252

Control group

2(0–16)

6(1–15)

5(0–10)

0.002

I-II: 0.003

I-III: 0.281

II-III: 1.000

HAM-A

Patient group

4(0–21)

11(1–15)

5.5(0–15)

0.025

I-II: 0.020

I-III: 1.000

II-III: 0.584

Control group

2(0–20)

6(1–16)

6(0–19)

0.146

-

RSA

Patient group

119(83–163)

122(76–157)

131(77–156)

0.358

-

Control group

140(87–165)

134(103–156)

130(97–144)

0.111

-

PRPS

Patient group

33(20–50)

39(21–44)

33.5(30–41)

0.002

I-II: 0.001

I-III: 1.000

II-III: 0.351

Control group

28(13–45)

29(13–39)

36.5(13–39)

0.148

-

  1. Bold values indicate statistically significant differences (p < 0.05)
  2. HAM-D Hamilton Depression Rating Scale, HAM-A Hamilton Anxiety Rating Scale, RSA Resilience Scale For Adults, PRPS Pandemic Risk Perception Scale